Inpharmus
Focus: Inpharmus is a Turkey-based biotechnology company founded in 2013 that markets branded and generic pharmaceutical products across multiple therapeutic areas including neurology, infectious diseases, and cardiovascular disease. The company's portfolio is heavily concentrated in cardiovascular products, with 71% of revenue derived from VASCEPA.
Profile data last refreshed 12h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Inpharmus
AI assessmentNot HiringNo open roles listed right now. Follow Inpharmus to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthWatch
Pipeline
Early-stage
0 total
LOE Risk
2 imminent
DYLOJECT
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$764M Part DStable
Peak6.8yr
Help build intelligence for Inpharmus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.